SCNI Regains Nasdaq Compliance As Traders Reassess Risk

Scinai Immunotherapeutics Ltd. stocks have been trading up by 7.33 percent amid heightened optimism surrounding its latest biotech developments.

Live Update At 15:02:04 EDT: On Tuesday, October 13, 2026 Scinai Immunotherapeutics Ltd. stock [NASDAQ: SCNI] is trending up by 7.33%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

SCNI has been trading like a classic small-cap biotech rollercoaster. Over the last several weeks, Scinai Immunotherapeutics has swung from a high near $2.33 in late September down to recent closes around $1.25. That’s a sharp volatility band, and traders need to respect it. The daily chart shows SCNI briefly spiking into the low $2s before fading back toward the mid-$1s, signaling strong momentum traders on both sides.

On 2026/10/13, SCNI opened at $1.56 and closed at $1.25 after hitting an intraday high of $1.76 and a low just above $1.14. That kind of range in one day tells you the order book is thin and reactive to news. Intraday, the 5‑minute candles show a huge premarket surge from roughly $1.13 to above $3.00 before settling into a heavy fade — textbook speculative action around a catalyst.

Fundamentally, Scinai Immunotherapeutics is still early stage. Revenue of about $1.31M against weak returns on assets and equity shows a business investing heavily without much scale yet. A price‑to‑sales near 1.22 and price‑to‑book around 0.64 suggest the market is not paying a big premium for SCNI’s story right now. For traders, that combination — low valuation metrics plus high volatility — is exactly what can fuel sharp, news‑driven moves.

Why Traders Are Watching SCNI Now

SCNI is back on a lot of screens for one simple reason: survival risk just dropped. Scinai Immunotherapeutics has officially regained compliance with Nasdaq’s $1.00 minimum bid price requirement, and that closes the immediate delisting threat that had been hanging over the stock. For a micro‑cap biotech, Nasdaq status isn’t about prestige. It’s about liquidity, access to capital, and whether bigger funds are even allowed to touch the name.

Regaining compliance required 19 consecutive trading days above $1.00. That means SCNI didn’t just pop intraday over the line; it held that level, which tells traders there was at least a baseline of sustained demand. Once Nasdaq confirmed the rule was satisfied, the delisting file was effectively shut. That removes a big psychological weight. No one wants to be stuck in a name forced off a major exchange.

With the listing drama out of the way, the story pivots back to execution. Scinai Immunotherapeutics is pushing forward its NanoAb immunology programs — an area traders know can produce binary, catalyst‑driven charts once clinical milestones hit. At the same time, SCNI is working to grow its CDMO operations, a services arm that can support other drug developers. That dual track matters. Pipeline upside is long‑dated and risky, but CDMO work can generate steadier, shorter‑cycle revenue.

For active traders, SCNI now sits in a classic “de‑risked, still speculative” pocket. The delisting cloud is gone, yet the float is clearly nimble enough to move fast when headlines cross.

Conclusion

SCNI has bought itself time, and in small‑cap biotech, time is everything. Scinai Immunotherapeutics is no longer staring down an immediate Nasdaq delisting, which dramatically changes the trading calculus. Without that cliff edge, forced selling pressure tied to compliance fears fades, and the focus shifts back to whether SCNI can turn its NanoAb platform and CDMO operations into real, scalable cash flow.

The balance sheet shows a tiny company — roughly $11.6M in assets, limited cash, and negative retained earnings. That tells traders dilution risk never really disappears in a name like Scinai Immunotherapeutics. But the market is now valuing SCNI at less than book value, while still reacting violently to every piece of news. That’s the kind of setup momentum traders hunt: asymmetric moves around clearly defined catalysts.

For newer traders watching SCNI, the lesson is process. Study how the stock behaved as the Nasdaq compliance story evolved, mark the levels where volume surged, and track how quickly the spikes faded. As Tim Sykes loves to tell his students, “The market doesn’t care about your opinion, only your preparation. Study the past so you’re ready when the next play shows up.” As millionaire penny stock trader and teacher Tim Sykes, says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.”. Scinai Immunotherapeutics is one more live case study in how a regulatory headline can reset risk and fuel a fresh trading plan — if you’re prepared and disciplined enough to trade it, not marry it.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks